Lynparza: Ph III OLYMPIAD data

Data from 302 patients with HER2-negative metastatic breast cancer with germline BRCA1 or BRCA2 mutations in the open-label, international Phase III OLYMPIAD trial showed that twice-daily 300 mg oral Lynparza met the primary endpoint of improving PFS vs. physician's choice of capecitabine, vinorelbine or eribulin...